Phase I trial of the targeted alpha-particle nano-generator actinium-225 ((225)Ac-lintuzumab) (anti-CD33; HuM195) in acute myeloid leukemia (AML) Meeting Abstract

  


Authors: Jurcic, J. G.; Rosenblat, T. L.; McDevitt, M. R.; Pandit-Taskar, N.; Carrasquillo, J. A.; Chanel, S. M.; Ryan, C.; Frattini, M. G.; Cicic, D.; Larson, S. M.; Scheinberg, D. A.
Abstract Title: Phase I trial of the targeted alpha-particle nano-generator actinium-225 ((225)Ac-lintuzumab) (anti-CD33; HuM195) in acute myeloid leukemia (AML)
Meeting Title: 47th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 29
Issue: 15 Suppl.
Meeting Dates: 2011 Jun 3-7
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2011-05-20
Language: English
ACCESSION: WOS:000208880302023
DOI: 10.1200/jco.2011.29.15_suppl.6516
PROVIDER: wos
Notes: Meeting Abstract: 6516 -- Source: Wos
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Michael R Mcdevitt
    144 Mcdevitt
  2. Joseph G Jurcic
    134 Jurcic
  3. Mark Frattini
    45 Frattini
  4. Neeta Pandit-Taskar
    342 Pandit-Taskar
  5. Suzanne M Chanel
    31 Chanel
  6. David Scheinberg
    499 Scheinberg
  7. Jorge Carrasquillo
    140 Carrasquillo
  8. Todd Louis Rosenblat
    21 Rosenblat
  9. Steven M Larson
    958 Larson
Related MSK Work